Evaluating only Biofourmis’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
FOUNDING
FUNDING
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
Biofourmis raised $300M to build AI-powered remote patient monitoring for chronic disease management. The technology genuinely worked — biosensor wearables combined with ML models predicted deterioration earlier than standard protocols. But healthcare enterprise sales are notoriously slow, hospital IT integration backlogs are measured in years, and reimbursement codes for RPM were still being established. The company burned through capital waiting for enterprise deployments that moved at hospital speed. By 2024 Biofourmis had sold off its care delivery division and was a fraction of its peak headcount.
Lesson
“Remote patient monitoring requires a reimbursement strategy as rigorous as the technology strategy — without it, hospital deployments never scale.”